Abstract:Introduction: Hirschsprung disease (HD) manifests as a developmental anomaly affecting the enteric nervous system, where there is an absence of ganglion cells in the lower part of the intestine. This deficiency leads to functional blockages within the intestines. HD is usually confirmed or ruled out through rectal biopsy. The identification of any ganglion cells through hematoxylin and eosin (H&E) staining rules out HD. If ganglion cells are absent, further staining with acetylcholine-esterase (AChE) histochemistry or calretinin immunohistochemistry (IHC) forms part of the standard procedure for determining a diagnosis of HD. In 2017, our Institute of Pathology at University Hospital of Heidelberg changed our HD diagnostic procedure from AChE histochemistry to calretinin IHC. In this paper, we report the impact of the diagnostic procedure change on surgical HD therapy procedures and on the clinical outcome of HD patients. Methods: We conducted a retrospective review of the diagnostic procedures, clinical data, and postoperative progress of 29 patients who underwent surgical treatment for HD in the Department of Pediatric Surgery, University of Heidelberg, between 2012 and 2021. The patient sample was divided into two groups, each covering a treatment period of 5 years. In 2012–2016, HD diagnosis was performed exclusively using AChE histochemistry (AChE group, n = 17). In 2017–2021, HD diagnosis was performed exclusively using calretinin IHC (CR group, n = 12). Results: There were no significant differences between the groups in sex distribution, weeks of gestation, birth weight, length of the aganglionic segment, or associated congenital anomalies. Almost half of the children in the AChE group, twice as many as in the CR group, required an enterostomy before transanal endorectal pull-through procedure (TERPT). In the AChE group, 4 patients (23.5%) required repeat bowel sampling to confirm the diagnosis. Compared to the AChE group, more children in the CR group suffered from constipation post TERPT. Discussion: Elevated AChE expression is linked to hypertrophied extrinsic cholinergic nerve fibers in the aganglionic segment in the majority of patients with HD. The manifestation of increased AChE expression develops over time. Therefore, in neonatal patients with HD, especially those in the first 3 weeks of life, an increase in AChE reaction is not detected. Calretinin IHC reliably identifies the presence or absence of ganglion cells and offers multiple benefits over AChE histochemistry. These include the ability to perform the test on paraffin-embedded tissue sections, a straightforward staining pattern, a clear binary interpretation (negative or positive), cost-effectiveness, and utility regardless of patient age. Conclusions: The ability of calretinin IHC to diagnose HD early and time-independently prevented repeated intestinal biopsies in our patient population and allowed us to perform a one-stage TERPT in the first months of life, reducing the number of enterostomies and restoring colonic continuity early. Patients undergoing transanal pull-through under the age of 3 months require a close follow-up to detect cases with bowel movement problems.

The Pathologist's Role in the Diagnosis of Hirschsprung's Disease

Opportunities for Novel Diagnostic and Cell-Based Therapies for Hirschsprung Disease.

Clinical Relevance of Pathological Diagnosis of Hirschsprung’s Disease with Acetylcholine-Esterase Histochemistry or Calretinin Immunohistochemistry

Chinese expert consensus statement on the diagnosis and treatment of Hirschsprung disease

Therapeutic approaches in Hirschsprung's disease: clinical cases

The Diagnostic Pathway of Hirschsprung's Disease in Paediatric Patients: A Single-Centre Experience

HIRSCHSPRUNG DISEASE AND HEMATOXYLIN-AND-EOSIN-STAINED SECTIONBASED DIAGNOSIS

The Application of Immunohistochemistry in the Diagnosis of Hirschsprung's Disease and Allied Diseases

The Diagnostic Value of Immunohistochemistry Markers in Hirschsprung Disease; A Systematic Review and Meta-analysis

The utility of the hematoxylin and eosin staining in patients with suspected Hirschsprung disease

Guidance of a pathological grading system of ganglion cells for intraoperative rapid biopsy of Hirschsprung disease for determining surgical margin and predicting bowel function

European Paediatric Surgeons' Association Survey on the Management of Hirschsprung Disease

Clinical Evaluation of Diagnostic Methods for Hirschsprung's Disease

Histopathology of Ganglion Cells in the Proximal Resected Bowel Correlates With the Clinical Outcome in Hirschsprung Disease: A Pilot Study

Hirschsprung's disease associated enterocolitis: A comprehensive review

Rectal biopsies for Hirschsprung disease: Patient characteristics by diagnosis and attending specialty

Diagnosis of Hirschsprung disease by analyzing acetylcholinesterase staining using artificial intelligence

Genetics of Hirschsprung's disease

A Pilot Study: Transcriptional Profiling, Functional Analysis, and Organoid Modeling of Intestinal Mucosa in Hirschsprung Disease

Is hematoxylin-eosin staining in rectal mucosal and submucosal biopsies still useful for the diagnosis of Hirschsprung disease?

Clinical Evaluation of Laparoscopic Surgery for Hirschsprung Disease Combined with Colorectal Anastomosis with a Stapling Technique in Infants.